BCL2 rs1026825: What Your Genotype Means
The rs1026825 variant is a single-nucleotide polymorphism located within the BCL2 gene. Research has identified this variant as a potential risk factor associated with the development of chronic lymphocytic leukemia (CLL).
What each genotype means
Baseline CLL risk profile
This genotype represents the common genetic state at this position in the BCL2 gene. Research indicates that this variant is associated with the initiation of chronic lymphocytic leukemia, but this specific genotype does not carry the risk-associated allele identified in population studies. This finding relates to disease susceptibility and does not influence disease progression or treatment response.
This is the most common genotype observed in most global populations.
Increased CLL risk marker
Carrying one copy of the G allele at this position has been identified as a risk factor for the development of chronic lymphocytic leukemia. This variant is thought to influence immune cell populations and cytokine signaling pathways, which may contribute to disease initiation. This association does not predict disease aggressiveness or how a patient might respond to therapy.
This genotype is found at varying frequencies across different ancestral groups, appearing in a significant minority of the population.
Elevated CLL risk marker
Carrying two copies of the G allele is associated with an increased statistical risk of developing chronic lymphocytic leukemia compared to those without the variant. The biological mechanism is linked to the role of BCL2 in autophagy and immune regulation, which may facilitate the early stages of the disease. This result is for informational purposes regarding risk and is not a diagnostic indicator.
This genotype is less common than the A/A or A/G genotypes in most studied populations.
Understanding the rs1026825 Variant
The rs1026825 variant is a specific change in the DNA sequence located within the BCL2 gene. In genetics, a single-nucleotide polymorphism (SNP) like rs1026825 represents a variation at a single position in the genome, where one nucleotide is replaced by another. This specific variant has been categorized in recent large-scale studies as an autophagy-related genetic marker. Autophagy is a critical cellular process that helps maintain homeostasis by removing damaged components. Because the BCL2 gene is deeply involved in regulating cell survival and death, variations in this region are of significant interest to researchers studying how cells manage stress and potential malignancy. While this SNP is a point of interest in genomic research, it is important to remember that it is just one of many factors that contribute to the complex biological landscape of human health.
The Role of the BCL2 Gene
The BCL2 gene provides instructions for making the BCL-2 protein, which is a central regulator of apoptosis, or programmed cell death. This protein acts as a gatekeeper, controlling the permeability of the mitochondrial membrane to determine whether a cell should survive or undergo self-destruction. By balancing pro-apoptotic and anti-apoptotic signals, the BCL-2 protein ensures that cells function correctly and that damaged or unnecessary cells are cleared away. Because of its fundamental role in cell life cycles, the BCL2 gene is frequently studied in the context of cancer research. When the regulation of apoptosis is disrupted, cells may survive longer than they should, which can contribute to the development of various conditions, including certain types of leukemia. Understanding how BCL2 functions provides a foundation for why researchers investigate specific variants like rs1026825 in relation to disease susceptibility.
Research and Statistical Associations
Scientific research, including large-scale meta-analyses of genome-wide association studies (GWAS), has investigated the link between rs1026825 and chronic lymphocytic leukemia (CLL). These studies have observed a statistical association between the presence of this variant and an increased risk of developing CLL. It is important to note that the evidence strength for this association is considered moderate. While researchers have identified a correlation, the biological mechanism by which this specific SNP influences CLL risk is still being explored. Some studies suggest that these variants may influence T-cell subsets or cytokine production, which are vital components of the immune system. However, results can vary across different populations, and the presence of this variant does not mean an individual will develop a disease. These findings are based on population-level data and are intended to advance our understanding of genetic risk factors rather than to serve as a diagnostic tool for individuals.
Interpreting Your Genetic Information
If you have information about your genotype for rs1026825, it is essential to view it within the context of current scientific understanding. Genetic variants are common, and most do not have a direct or significant impact on an individual's health. The association between rs1026825 and CLL is a statistical observation derived from large groups of people, not a clinical prediction for a single person. You cannot use this information to diagnose yourself or predict your future health outcomes. If you are concerned about your health or family history, the most appropriate step is to consult with a healthcare professional or a genetic counselor. They can help you interpret your results in the context of your overall medical history and lifestyle. Never make changes to your health management or medication based on genetic data without first discussing it with your clinician or pharmacist.
How common is this variant?
The frequency of the rs1026825 variant is variable across different global populations, meaning the prevalence of the G and A alleles differs significantly depending on ancestral background.
Frequently asked questions
What is the BCL2 gene?
The BCL2 gene encodes a protein that regulates apoptosis, which is the process of programmed cell death. It plays a crucial role in maintaining cellular health by controlling whether cells survive or die.
Does having the rs1026825 variant mean I will get leukemia?
No. The association between rs1026825 and chronic lymphocytic leukemia is a statistical finding from population studies. It does not mean that an individual with this variant will develop the disease.
How is this variant linked to autophagy?
Research has identified rs1026825 as an autophagy-related variant. Autophagy is a cellular process that clears out damaged components, and variations in genes like BCL2 may influence how efficiently this process occurs.
Should I be worried about my rs1026825 genotype?
Genetic variants are common and are only one part of your overall health profile. If you have concerns about your genetic results, you should discuss them with a qualified healthcare provider or genetic counselor.
Sources & further reading
Educational information only, last refreshed 10/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1026825?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in BCL2
A newly identified autophagy-related variant linked to chronic lymphocytic leukemia risk and altered cytokine production.
This SNP is associated with chronic lymphocytic leukemia development and impacts immune cell subset regulation.
This BCL2 variant is associated with survival outcomes in patients treated with R-CHOP for lymphoma, specifically showing treatment-dependent risk modulation.
This BCL2 intronic variant shows significant interaction with R-CHOP treatment efficacy in patients with diffuse large B-cell lymphoma.